| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_c414aaa73a64e179b48ae53747f8414c
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_f48f08f97511087d5dc1e422cd9bb61c
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_6115b7f4561db088f26a575e9339fed0 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-5156
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-5154
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-57 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-39
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P19-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P17-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-0011
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P11-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-39533 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-38 |
| filingDate |
2009-12-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_bd99e566f3891023ba8de1dbf6a9134d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8e0b109ec405371e97cad3246d6cadcf |
| publicationDate |
2010-06-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2010068680-A1 |
| titleOfInvention |
Thelper cell type 17 lineage-specific adjuvants, compositions and methods |
| abstract |
The present invention relates to compositions and methods for the modulation of T N 17 responses. The invention provides compositions for the induction of T N 17 responses containing a TLR agonist and an apoptotic cell-associated agent or containing a mierobe- infected apoptotic cell. The compositions of the present invention may also contain dendritic cells capable of inducing T N 17 responses. In other embodiments, the invention provides compositions for the inhibition of T N 17 responses containing one or more blocking agents. Methods and compositions for the modulation of T N 17 responses and for the treatment of T N 17 -associated diseases and for cancer are also provided. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2014145038-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/AU-2017204110-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10226528-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11419925-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/AU-2014233424-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11027011-B2 |
| priorityDate |
2008-12-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |